Tender Details
Description / Scope of Work
The National Institute of Child Health (NICH), Karachi, a leading health institution under the Health Welfare Committee, invites sealed bids for the purchase of medicines and drugs from the Pakistan Bait-ul-Mal Fund for the financial year 2026-27. The estimated total cost of procurement is 30.00 million Pakistani rupees, with an allocated fund of 7.00 million rupees approximately from Pakistan Bait-ul-Mal Provincial Offices in Sindh and Karachi. This procurement encompasses a comprehensive range of essential medicines and drugs required to support NICH's operations and patient care services in Karachi, a major healthcare hub in the province.
The procurement will be conducted through a single-stage two-envelope bidding method as per SPPRA rules. Bidders must comply with all relevant regulatory requirements and procurement standards. Eligible vendors should possess valid registration with appropriate authorities and demonstrated capacity to supply pharmaceutical products of required quality and standards.
Bids will be accepted from 1 July 2026 to 30 June 2027. Interested bidders must obtain bid documents from NICH Karachi and submit sealed bids in two envelopes as per the prescribed format. Detailed specifications of required medicines and drugs are provided in Annexure A. All submissions must be made to the office of the Procurement Committee at NICH, Karachi. The procurement committee comprises senior officials including Prof. Mohsina Noor Ibrahim (Chairperson), Prof. Muhammad Ashfaq, Ms. Shahzadi Kanwal, Ms. Tahira Razzak, and Mr. Mushtaque Ahmed (Secretary).
For Bidders: Our Analysis PAKISTANTENDER INSIGHT
Independent analysis by PakistanTender — not part of the official notice. Always confirm details against the original tender document.
NICH Karachi is procuring medicines and drugs valued at 30 million rupees over the 2026-27 financial year, with 7 million allocated initially from Bait-ul-Mal funds.
This is a recurring annual procurement through single-stage two-envelope tender. Bidders should note the extended bid window (July 2026 to June 2027) and requirement to reference detailed specifications in Annexure A. Competition likely from established pharmaceutical suppliers. Compliance with SPPRA procurement rules and quality standards is non-negotiable.
Who can bid: Bidders must typically be registered with relevant pharmaceutical regulatory authorities (SECP/NTN) and hold valid licenses from the Drug Regulatory Authority of Pakistan (DRAP). Government suppliers and vendors with demonstrated pharmaceutical supply experience to healthcare institutions appear preferred. Specific eligibility criteria not detailed in the main notice; refer to full bid documents.